Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

646.00GBp
26 May 2017
Change (% chg)

21.00 (+3.36%)
Prev Close
625.00
Open
625.00
Day's High
648.50
Day's Low
625.00
Volume
800,664
Avg. Vol
910,566
52-wk High
739.50
52-wk Low
528.36

BTG.L

Chart for BTG.L

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.17
Market Cap(Mil.): £2,601.54
Shares Outstanding(Mil.): 385.13
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): 118.91 29.41 30.38
EPS (TTM): 0.06 -- --
ROI: 2.12 13.85 13.36
ROE: 2.55 14.79 14.50

BTG's pulmonary embolism device work faster and at lower doses in study

LONDON British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard.

22 May 2017

BTG's pulmonary embolism device work faster and at lower doses in study

LONDON, May 22 British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard.

22 May 2017

BRIEF-BTG updates on Optalyse pulmonary embolism study results

* Optalyse PE study demonstrates safety and efficacy of shorter, lower dose Ekos ® therapy for pulmonary embolism

22 May 2017

BRIEF-BTG sees double-digit product sales growth in medium term

* Are well positioned to capture further value in growing interventional medicine space and to deliver sustained business growth

16 May 2017

More From Around the Web

Earnings vs. Estimates